Submitted by Anonymous (not verified) on 5 February 2026 - 16:05
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 14, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 14, Status: Authorised